Proteasome Inhibitor Bortezomib Suppresses Nuclear Factor-Kappa B Activation and Ameliorates Eye Inflammation in Experimental Autoimmune Uveitis

<div>EMSA for the evaluation of the NF-κB DNA-binding activity in naïve mice and different groups of EAU mice. Lane 1: p50 subunit of NF-κB. Lane 2: free probe (FP). Lane 3: naïve C57BL/6 mice. Lane 4: EAU mice with saline treatment. Lane 5: EAU mice treated with low-dose bortezomib (Vel [L]). Lane 6: EAU mice treated with high-dose bortezomib (Vel [H]). Lane 7: 100-fold molar excess of unlabeled NF-κB probe. Lane 8: anti-p65 subunit of NF-κB. The sample was pooled from both eyes of five mice in each group. Data are representative of results in three independent experiments.</div>

Mediators of Inflammation

fig4

Figure 4

Figure 4: Proteasome Inhibitor Bortezomib Suppresses Nuclear Factor-Kappa B Activation and Ameliorates Eye Inflammation in Experimental Autoimmune Uveitis 

Figure 4 | Proteasome Inhibitor Bortezomib Suppresses Nuclear Factor-Kappa B Activation and Ameliorates Eye Inflammation in Experimental Autoimmune Uveitis 